28 Sep 2022
Apotex Pharmaceutical to sell to SK Capital Partners
On April 3, 2023, Apotex Pharmaceutical Holdings Inc. confirmed the completion of its acquisition by an affiliate of SK Capital Partners, LP. Concurrently, the company announced the appointment of Allan Oberman as the new President, CEO, and Board member. Oberman, with 40 years of corporate leadership, including two decades in the pharmaceutical sector, previously held CEO roles at Concordia International Corp., Sagent Pharmaceuticals Inc., and significant positions at Teva's various divisions. Oberman, an MBA graduate from the Schulich School of Business and a BA holder from Western University, has expressed enthusiasm about joining Apotex, a company he once competed against and deeply admires for its innovative approach and commitment to affordable medicine.
Apotex's Chairman, Aaron Davenport, commended Oberman's vast experience, emphasizing that his leadership in major pharmaceutical entities would further Apotex's growth as a globally recognized health company based in Canada. Jeff Watson, who served as Apotex's CEO since 2018, will transition to the company's Board of Directors, where he'll offer his guidance and expertise.
